^
    1d
    CheckMate 9DW: A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P3, N=732, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Nov 2026 --> Jul 2026 | Trial primary completion date: Nov 2026 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • sorafenib • Lenvima (lenvatinib)
    1d
    MONAMI: Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, Assistance Publique - Hôpitaux de Paris | N=43 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Tumor mutational burden • dMMR • First-in-human
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    volrustomig (MEDI5752) • monalizumab (IPH2201)
    3d
    Comparative efficacy and safety of nivolumab-based combination therapies (with ipilimumab or binimetinib) in patients with microsatellite-stable and microsatellite-instability-high metastatic colorectal cancer: a systematic review and meta-analysis. (PubMed, Clin Transl Oncol)
    In metastatic CRC patients who receive nivolumab-based combination therapies demonstrate partial tumor responses that increase while their safety profile remains acceptable, but their overall response rates do not improve. The research demonstrates how immunotherapy serves as a standard treatment method for MSI-H disease while emphasizing the need to develop biomarker-driven approaches that enhance treatment selection methods, especially for MSS CRC.
    Retrospective data • Review • Journal • Microsatellite instability • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • MSI-H
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Mektovi (binimetinib)
    4d
    KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma. (PubMed, Eur Urol)
    CALYPSO (NCT02819596) was a prospective, multi-arm trial that evaluated durvalumab alone or in combination with tremelimumab or savolitinib in metastatic ccRCC and pRCC. Also, an increase in KIM-1 during therapy was linked to worse progression-free survival (HR 1.7; 95% CI, 1.13-2.58; p = 0.01) and OS (HR 1.95; 95% CI, 1.23-3.08; p = 0.004) in ccRCC. This exploratory analysis supports the utility of KIM-1 in advanced ccRCC and pRCC.
    Journal • PD(L)-1 Biomarker
    |
    KIM1 (Kidney injury molecule 1)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Orpathys (savolitinib)
    4d
    Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=30, Suspended, City of Hope Medical Center | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    4d
    QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC. (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Fudan University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    Qibeian (iparomlimab/tuvonralimab)
    4d
    VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=18, Not yet recruiting, Mayo Clinic
    New P2 trial
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar) • Voyager-V1
    5d
    A Study to Evaluate the Safety, Tolerability and Efficacy of IMD303 in Participants With Advanced Malignant Solid Tumors (ACTRN12626000403336)
    P1, N=30, Recruiting, Catalysis Therapeutics Pty Ltd/Affinity (Chengdu) Pharmaceutical Co., Ltd
    New P1 trial
    5d
    BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Brown University | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Jan 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    6d
    Therapeutic targeting of PD-1/PD-L1 and CTLA-4 in colorectal cancer: tumor-intrinsic and immune checkpoint signaling. (PubMed, Expert Opin Biol Ther)
    It discusses the major trials of nivolumab, pembrolizumab, and ipilimumab, including combinations from the CheckMate-142 and CheckMate-8HW trials. The combination of PD-1 and CTLA-4 inhibitors in MSI-H/dMMR metastatic colorectal cancer has demonstrated long-term clinical efficacy and a genuine survival benefit. However, in MSS metastatic colorectal cancer, there has been limited response, emphasizing the importance of innovative combination therapies to address both primary and secondary resistance.
    Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    TMB-H • MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab)
    6d
    ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab (clinicaltrials.gov)
    P4, N=90, Not yet recruiting, NYU Langone Health
    New P4 trial • Circulating tumor DNA
    |
    BRAF (B-raf proto-oncogene) • IFNA1 (Interferon Alpha 1)
    |
    Signatera™
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    6d
    eVOLVE-Meso: MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (clinicaltrials.gov)
    P3, N=825, Recruiting, AstraZeneca | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • pemetrexed • volrustomig (MEDI5752)